About us

Here you will find information about our member organisations, the member representatives, as well as the process we undertake when making recommendations.

Decision-Making Process

The Lancashire Medicines Management Group (LMMG) provides a platform for the consensus decision-making process on the use of medicines across the Lancashire NHS footprint.

The group makes recommendations to the eight Clinical Commissioning Groups (CCGs) for the use of medicines by way of horizon scanning for new drugs or receipt of requests from prescribers to use drugs where a funding decision has not yet been made. There are five local decision-making groups in Lancashire who then decide whether to adopt the recommendations of the LMMG by considering their local needs. The five groups then feedback their decisions to the LMMG for inclusion on the website.


Request for new medicine to be commissioned submitted to Lancashire CSU following local prioritisation by one or more LMMG member organisations*

Request for new medicine is considered at the next LMMG meeting for prioritisation onto the work plan. Requests will be prioritised based on a number of criteria including but not exclusive to: Whether an existing position is already in place across Lancashire, if the product is a genuinely novel treatment, if there are existing variations in use of the medicine across Lancashire, if there is a need for local interpretation or clarification of existing NICE guidance, if the medicine is likely to impact on the wider patient care pathway  or the use of the medicine could create a significant cost pressure or cost saving.

Once a medicine has been prioritised for review the CSU will produce a draft “position statement” for consultation (with support from CCGs and involvement from relevant clinicians across Lancashire if appropriate) and send to LMMG member organisations for a 5 week consultation period.

CSU collates and reviews comments and refines draft “position statement” if required within a maximum of 2 weeks from the closing date.

Final draft “position statement” considered by the next available LMMG meeting and recommendations agreed.

LMMG recommendations uploaded to the LMMG website within ONE week of LMMG meeting and LMMG member organisations informed that the final documents are available.

CCGs consider the LMMG recommendation within their local decision making groups for local adoption or adaption and inform LMMG (via CSU) of local action on recommendations once agreed.

CSU updates website with details of local decisions within ONE week of receiving the information from the CCG.


Requests may be generated through; the annual horizon scanning process for new medicines, IFRs considered to be service developments, individual requests from provider clinicians or individual CCGs, as a result of redesign of care pathways involving medicines, or for review of previous recommendations where there has been a significant change in clinical evidence or proposed pattern of use.

Requests prioritised for consideration by stakeholder considerations will take priority over those identified only through the horizon scanning process.

In some instances, medical devices which are available on NHS prescription may be prioritised for review by the LMMG. Where this happens the review process is adapted to take into account the unique challenges associated with assessing the safety, efficacy and usability of devices.

Medical Devices Review Process (180.2 KiB)